Barclays PLC Has $3.71 Million Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Barclays PLC cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 290,384 shares of the biopharmaceutical company’s stock after selling 12,188 shares during the period. Barclays PLC’s holdings in Dynavax Technologies were worth $3,708,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC acquired a new position in Dynavax Technologies during the fourth quarter worth $990,000. Nordea Investment Management AB increased its position in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in shares of Dynavax Technologies during the 4th quarter worth about $275,000. Fox Run Management L.L.C. bought a new position in Dynavax Technologies during the 4th quarter valued at about $883,000. Finally, Nisa Investment Advisors LLC boosted its position in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,076 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $11.27 on Tuesday. The firm has a 50 day simple moving average of $12.74 and a 200 day simple moving average of $12.58. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.38 billion, a P/E ratio of 62.61 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Sell-side analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVAX has been the subject of several recent analyst reports. The Goldman Sachs Group dropped their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.